On 23 and 24 July 2025, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) convened to review seven peptide-related compounds being considered for potential inclusion on the 503A Bulks List. After two days of discussion, six of the seven received positive recommendations from the committee. One did not. For a field that has operated in a
NAD+ appears regularly in discussions about longevity, cellular energy, and metabolic health research, often alongside peptides and other compounds associated with the same field. This proximity can create the impression that NAD+ belongs to the same category. However, NAD+ is not a peptide, it is a distinct class of molecule with a different chemical structure,
When people encounter Peptide Therapy research for the first time, it can seem like a recent development, especially with the new “boom” online. The history of peptides in scientific research stretches back well over a century, with roots in some of the most significant discoveries in the entire history of medicine. Peptide signalling is not
Cardiovascular science is one of the most extensively researched areas in medicine. Within it, a relatively niche but scientifically distinct field has developed over several decades: the study of heart bioregulators. Heart bioregulators are short peptide complexes derived from cardiac tissue and are studied for their role in cardiac gene expression and cardiomyocyte (heart muscle
Peptides for beginners is a topic that deserves more explanation than it usually receives. Peptides have become one of the most discussed subjects in health, longevity, and regenerative medicine, generating significant interest across research communities, functional medicine practitioners, and individuals exploring more targeted approaches to their health. With that interest has come a great deal
BPC-157 is one of the most extensively researched peptides in the field of regenerative science. It is documented effects across tissue repair, wound healing, gastrointestinal protection, and angiogenesis have made it a compound of significant interest to researchers, practitioners, and individuals pursuing health optimisation. As its profile has grown, so has the range of ways
Fatigue is one of the most commonly reported health complaints across all age groups. For many people, tiredness is transient and explained by straightforward causes: poor sleep, high stress, or a demanding period of work or illness. For others, the fatigue is persistent, disproportionate to effort, and resistant to rest. When tiredness becomes a chronic
A significant peptide update in 2026 has set in motion a significant regulatory shift for some of the most widely researched compounds in the peptide space. Following an announcement by Robert F. Kennedy Jr., United States Secretary of Health and Human Services, 12 peptides previously classified under FDA Category 2 will be removed from that
There is no shortage of information about starting a peptide cycle. Protocols, dosing schedules, and expected benefits are well documented. What receives far less attention is the other end of the process. Stopping Peptide Therapy is a biological event in its own right, and for a meaningful proportion of people, the transition off a cycle
In a February 27, 2026 appearance on the Joe Rogan Experience podcast, Health and Human Services Secretary Robert F. Kennedy Jr. articulated intentions to pursue reclassification of approximately 14 peptides from FDA Category 2 status back to Category 1, a policy reversal that, if implemented, would restore legal compounding access to compounds prohibited since September
